Abstract. Bone that was virtually depleted ofthe vitamin K-dependent protein, osteocalcin, and 93% reduced in the concentration of its characteristic amino acid, -y-carboxyglutamic acid, was obtained from rats treated with warfarin for 6 wk. Osteocalcin-deficient bone particles were resistant to resorption when implanted subcutaneously in normal rats. The relative resorption was 60% of control bone, as measured by histomorphometry as percent of bone particles in the field. Additionally, the number ofmultinucleated cells around the bone particles was reduced by 54%. These data suggest that osteocalcin is an essential component for bone matrix to elicit progenitor-cell recruitment and differentiation necessary for bone resorption.
Introduction
Osteocalcin (bone Gla protein), the most abundant noncollagenous protein in bone, is characterized by three residues of ycarboxyglutamic acid (Gla)' per 5,700 molecule (1, 2) . The protein is synthesized de novo in bone tissue dependent upon vitamin K and CO2 and appears concomitant with the first formation of bone. The anticoagulant warfarin inhibits Gla formation in bone (3) and it also decreases the bone concentration ofosteocalcin (4) . Although many properties ofthe protein have been defined (1, 2), a physiologic role for osteocalcin has yet to be identified.
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1. Abbreviations used in this paper: BP, bone particles; Gla, y-carboxyglutamic acid.
Recently, it has been demonstrated that osteocalcin and specifically the amino acid Gla are chemoattractants for monocytes (5, 6) . Therefore, the chemoattractant property of osteocalcin may be central to recruitment, differentiation, and regulation of bone resorbing cells, and as such this hypothesis was tested in vivo. Bone resorption can be quantitated by histomorphometric analysis of devitalized bone particles after implantation into subcutaneous pockets in rats (7, 8 (9) . Rat bone osteocalcin was measured by a radioimmunoassay procedure that used purified rat osteocalcin as standard and tracer, with goat anti-rat osteocalcin antiserum, generously provided by Dr. Peter Hauschka (Children's Hospital, Boston). Antigen preparation and species-specific antisera were raised by following described procedures (10) . The procedure for measurement of bone osteocalcin follows the assay described by Hauschka et al. (10) with the exception that the addition of 20,000 cpm of '25I-osteocalcin was delayed 24 h. This increased the sensitivity with assays being linear between 0.5 and 25 ng/ ml ofosteocalcin with a limit ofdetectability of0.2 ng/ml ofosteocalcin.
Antibodies to chick (10) , bovine (11) , and rat (12 and unpublished observations of this laboratory) osteocalcins do not distinguish native from thermally decarboxylated osteocalcins.
Resorption assay: implantation ofdevitalized bone particles BP. In each experiment, -50 mg of pooled BP were inserted into bilateral, subcutaneous pockets in two or three normal rats (Charles River CD strain, male, 28 d old) providing four to six specimens per group. 12 d later, BP and surrounding tissues were harvested as encapsulated buttons and prepared for nondecalcified histomorphometric analysis (7) . The percent area in contiguous fields representing bone particles was calculated with a Zeiss-Kontron digital image analyzer. Values are expressed as means of 80-120 fields (±SEM). The t test for unpaired data was used to estimate significance in each experiment.
Results
After 6 wk of sodium warfarin treatment, mean weight of the experimental group was 135±27 g, compared with the control group, which was 160±22 g. Bone parameters of total ash, calcium, phosphorus, total protein, and collagen were not significantly different in control and experimental groups (Table I) . In warfarin-treated animals, Gla content of the bone pool used for implants was 0.046±0.02 residues/103 amino acids, which is only 7.1% of the control value (0.65±0.05 residues/ 103 amino acids). Osteocalcin was virtually absent in warfarin bone, 0.05±0.0003 mg/g bone, which is 0.6% of the control concentration of 2.075±0.28 mg/g. The only difference observed in our results from the results described by Price and Williamson (4) was a 15% decreased growth rate in the warfarin-treated animals.
Implants removed on day 12 showed that bone particles from the warfarin-treated animals were resorbed to a much lesser extent than were BP from control animals. Fig. 1 represents typical fields of specimens of BP from control (A) and warfarintreated (B) animals, which show the particles and surrounding connective tissue. The osteocalcin-deficient BP were larger and showed much less evidence of surface resorptive lacunae than was seen in control specimens. Histomorphometric analysis (Table II) of three experiments showed a consistent defect in the resorption of BP from warfarin-treated rats (P < 0.001).
For example, in experiment one, the BP from control bone accounted for 27.9% ofthe microscopic field, which is equivalent to 44.2% resorption of the original BP volume. In contrast, 39.9% of the field was occupied by osteocalcin-deficient bone particles, which is equivalent to 20.2% resorption. Thus, only 46% of osteocalcin-deficient bone particles was resorbed relative to the control group. Multinucleated bone resorbing cells were located in lacunae in the controls (Fig. 1 C) with only occasional multinucleated cells evident around the osteocalcin-deficient particles (Fig. 1 D) . (14) who showed closure of the growth plate along with greater bone mass in warfarin-treated rats. However, that study also demonstrated an identical apposition rate in their control and warfarin-treated rats. Their observations are consistent with a decrease in resorption ofosteocalcin-deficient bone. A potential function for osteocalcin as a regulatory protein in resorptive processes of bone is also suggested by observations what percentage of serum osteocalcin or urine Gla excretion is contributed by resorption (1 1, 20) . The methods described here provide a novel approach for understanding osteocalcin as a bone matrix protein that functions as a factor in induction ofbone resorption. These results suggest that osteocalcin may be essential for progenitor cell interactions in the recruitment and differentiation of a functional boneresorbing cell.
